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Smooth muscle cells cultured from human
saphenous vein exhibit increased proliferation,
invasion, and mitogen-activated protein kinase
activation in vitro compared with paired internal
mammary artery cells
Neil A. Turner, PhD,a Selina Ho, BSc,a Philip Warburton,a David J. O’Regan, MD, FRCS,b and
Karen E. Porter, PhDa Leeds, United Kingdom
Objective: Smooth muscle cell (SMC) proliferation, invasion, and matrix metalloproteinase (MMP) secretion are key
events in the development of intimal hyperplasia, the lesion that causes coronary artery bypass graft (CABG) failure.
Saphenous vein (SV) grafts are the most commonly used bypass conduits but are markedly more susceptible to intimal
hyperplasia than internal mammary artery (IMA) grafts. We hypothesized that this may be due to inherent functional
differences between SV-SMCs and IMA-SMCs. In this study we used paired cultures of SV-SMCs and IMA-SMCs from
the same patients and compared their rates of proliferation, invasion, migration, and MMP-2 and MMP-9 secretion.
Methods: SMCs were cultured from explants of paired SV and IMA from 22 patients undergoing CABG. SMC populations
of equivalent passage were used to determine proliferation in response to 10% fetal calf serum (FCS), 10 ng/mL
platelet-derived growth factor (PDGF), and 10 ng/mL basic fibroblast growth factor (bFGF) by counting cells during
a 7-day period. Immunoblotting was used to quantify phosphorylation of p44/42-mitogen-activated protein kinase
(MAPK). Invasion and migration rates of paired SMCs were quantified using a modified Boyden chamber technique in
the presence or absence of a Matrigel basement membrane barrier (BD Biosciences, Oxford, UK). Conditioned media
from invasion assays were analyzed for secretion of MMP-2 and MMP-9 by gelatin zymography.
Results: Analysis of areas under curves for 7-day proliferation assays revealed that the number of SV-SMCs in response to
FCS, PDGF, and bFGF was 2.1, 2.0, and 2.3 times higher, respectively, than that of paired IMA-SMCs. Basal MAPK
activation in SV-SMCs was approximately double that of paired IMA-SMCs. SV-SMCs exhibited a 2.1-fold increase in
invasion rate (Matrigel barrier) compared with IMA-SMCs, but migration rates (no Matrigel barrier) and MMP-2 and
MMP-9 secretion were similar for the two cell types.
Conclusions: Human SV-SMCs are inherently more proliferative and invasive than paired IMA-SMCs, likely due to a relative
increase in p44/42-MAPK activation. These inherent functional differences between SMC of different origins may contribute
to the increased prevalence of intimal hyperplasia in SV grafts compared with IMA grafts. (J Vasc Surg 2007;45:1022-8.)
Clinical Relevance: Smooth muscle cell (SMC) proliferation, invasion, and matrix metalloproteinase (MMP) secretion are
key events in the development of intimal hyperplasia, the lesion that causes coronary artery bypass graft failure.
Saphenous vein (SV) grafts are markedly more susceptible to intimal hyperplasia than internal mammary artery (IMA)
grafts. In this study, we used paired cultures of SV-SMCs and IMA-SMCs and compared rates of proliferation, invasion,
migration, and MMP-2 and MMP-9 secretion. SV-SMCs were consistently more proliferative and invasive than
IMA-SMCs, although migration and MMP-2 and MMP-9 secretion were similar. These inherent functional differences
between SMCs of different vascular origins may contribute to the increased prevalence of intimal hyperplasia in SV grafts
compared with IMA grafts.Coronary artery bypass grafting (CABG) with the au-
tologous saphenous vein (SV) or internal mammary artery
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1022(IMA) is widely and routinely used to surgically revascular-
ize atherosclerotic coronary arteries. By virtue of its ready
availability and ease of harvesting, the SV has been and will
continue to be the most frequently used CABG conduit,
despite its predisposition to patency-threatening stenosis.1
Within the first year after CABG, up to 15% of SV grafts
occlude. Subsequent attrition rates are as high as 4% per
year, resulting in only 50% of grafts remaining patent after
10 years.1,2 As a result, 31% of all CABG procedures in the
United Kingdom are reoperative/revascularization proce-
dures.2,3
In contrast with the SV, the IMA demonstrates remark-
able resistance to stenosis and is therefore the preferred
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the procedure.2,4 However, the use of IMA is limited by its
availability, and given that most patients require multiple
grafts, the requirement for SV grafts remains. Despite in-
tensive research for more than two decades, SV bypass graft
failure continues to be a major clinical problem for which
there is no effective preventative strategy.
The underlying pathologic lesion of vein graft stenosis
is the characteristic development of intimal hyperplasia, a
complex process initiated in the vessel wall after bypass
grafting. Although the etiology of intimal hyperplasia is
multifactorial and not fully understood, endothelial dam-
age during vein harvesting and implantation undoubtedly
play a significant initiating role.1,5 After implantation into
the arterial circulation, the vein graft is exposed tomarkedly
different hemodynamics than in the venous circulation.
This includes high pressure, pulsatile flow and elevated
shear stresses to which the venous endothelium is not
adapted6 and results in impaired secretion of vasoprotective
factors such as prostacyclin and nitric oxide.6,7 Other causes
of endothelial injury specific to vein harvesting include
ischemia of the vein wall due to transient loss of luminal
blood and vasa vasorum, and also the pH of the distending
fluid used when graft integrity is checked.4
Exposure of subendothelial matrix facilitates deposi-
tion of leukocytes, platelets, and other blood components
that release cytokines and growth factors that are able to
induce vascular smooth muscle cell (SMC) dedifferentia-
tion from a contractile phenotype to a proliferative, inva-
sive, and secretory phenotype. Indeed, animal studies have
shown that up to 2months after implantation of vein grafts,
increased platelet activation is observed together with in-
creased production of platelet-derived growth factor
(PDGF) and basic fibroblast growth factor (bFGF) in the
developing hyperplastic lesions.8,9
The release of chemoattractants by adherent platelets,
damaged endothelium, and the underlying vascular SMCs
stimulates the secretion of specific matrix metalloprotein-
ases (MMPs) from the SMCs themselves, freeing them
from the normal constraint of the extracellular matrix. The
requirement for MMPs (particularly MMP-2 and MMP-9)
to promote invasion and proliferation of SMCs in the
intima of the vein graft wall has been demonstrated in
animal models in vivo10-12 and in human models in
vitro.13,14
Theories explaining why graft stenosis is more preva-
lent in the SV than the IMA have focussed upon the
handling and preparation of the graft, surgical trauma, and
altered hemodynamics in the arterial circulation.13,15,16
However, recognition is growing that the cellular constit-
uents of different vascular beds can exhibit diverse interves-
sel characteristics.17 Of importance is that SMCs from veins
and arteries are derived from different embryonic origins
and exhibit distinct molecular signatures.18 Thus, intrinsic
functional differences between venous and arterial SMCs
may contribute to the increased rate of graft stenosis ob-
served in SV vs IMA grafts.Previous attempts to explain the disparities seen in graft
failure19-21 have been somewhat limited by the experimen-
tal models used, hence prompting the requirement for a
side-by-side investigation of paired SV-SMCs and IMA-
SMCs from the same patient. The aim of this study was to
compare the in vitro proliferative, invasive, and migratory
properties of paired human SV-SMCs and IMA-SMCs
under controlled conditions. We hypothesized that SV-
SMCs would be intrinsically more proliferative, invasive,
andmigratory than IMA-SMC, thereby contributing to the
inferior patency rate of SV grafts compared with IMA grafts
used in CABG procedures.
METHODS
Materials. All cell culture reagents were purchased
from Invitrogen (Paisley, UK), except fetal calf serum
(FCS) that was from LabTech International (Ringmer,
UK). PDGF-BB, bFGF and interleukin-1 (IL-1) were
from Sigma (Poole, UK). Monoclonal phospho-Thr202/
Tyr204 p44/42-mitogen-activated protein kinase
(MAPK) antibody and polyclonal p44/42-MAPK expres-
sion antibody were purchased fromCell Signaling Technol-
ogy (Hitchin, UK). Invasion and migration assay chambers
and inserts were from BD Biosciences (Oxford, UK).
Cell culture. Paired samples of SV and IMA were
obtained from 22 patients undergoing elective CABG sur-
gery at the Leeds General Infirmary. Patients with diabetes
mellitus were excluded. Local ethical committee approval
and informed patient consent were obtained.
SV and IMA segments were chopped into small frag-
ments, and the resultant explanted cells were cultured as we
have described previously.22 Unsuccessful explants were
occasionally noted for IMA-SMCs or SV-SMCs, and con-
sequently, any unpaired cells were excluded from this
study. Cells were maintained at 37°C in Dulbecco Modi-
fied Eagle Medium (DMEM) containing 10% FCS in a
humidified atmosphere of 5% carbon dioxide in air. All
experiments were performed using paired populations of
SV-SMCs and IMA-SMCs of equal passage number (2 to
4) from different patients.
Proliferation assays. SMC proliferation assays were
performed as described previously.22 Briefly, paired SV-
SMCs and IMA-SMCs were seeded in parallel into 24-well
tissue culture plates at a density of 1  104 cells per well in
full growth medium (DMEM plus 10% FCS). Cells were
incubated overnight, then quiesced in serum-free medium
for 3 days before transfer to the appropriate growth-
stimulatory medium. Medium was replaced every 2 days,
and growth curves constructed by determining cell number
in quadruplicate wells. Cells were released from culture
wells with trypsin and counted using an improved Neubauer
hemocytometer. Trypsinized wells were observed micro-
scopically to confirm that all cells had been efficiently
collected.
Western blotting. The p44/42-MAPK cascade23 is a
key signalling pathway that promotes SMC proliferation.
Paired SV-SMCs and IMA-SMCs were seeded into six-well
plates at a density of 4  104 cells/well (equivalent to
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tion overnight, cells were quiesced in serum-free medium
for 3 days before preparing whole cell homogenates.24
Samples were protein-equalized and immunoblotted with
monoclonal phospho-specific p44/42-MAPK antibody
and polyclonal p44/42-MAPK expression antibody as we
have described previously.24
Immunolabeled bands were visualized by chemilumi-
nescence (Pierce, Cramlington, UK), and densitometry
measurements were performed using ImageQuant software
(Amersham Life Science, Amersham, UK). Homogenates
from paired SMCs were analyzed on the same gel and
membrane to facilitate accurate comparisons.
Invasion and migration assays. SMC invasion in-
volves two distinct processes: (1) degradation of a base-
ment membrane barrier by secretion of MMP-2/MMP-9
from the SMC and (2) migration of cells towards a chemo-
tactic stimulus. The in vitro invasive properties of paired
human SV-SMCs and IMA-SMCs were assessed using a
modified Boyden chamber technique, with pores occluded
with Matrigel basement membrane matrix (BD Bio-
sciences) as we have previously described.22
Cells (1  105) were loaded in the upper chamber in
medium supplemented with 0.4% FCS. The lower chamber
contained 0.4% FCS (control) or 0.4% FCS supplemented
with chemoattractant (10 ng/mL PDGF-BB plus 10
ng/mL IL-1). After incubation for 24 hours at 37°C in a
tissue culture incubator, duplicate membranes were pro-
cessed and evaluated by counting cells in 10 random fields
under high-power light microscopy.22 Conditioned media
were collected and centrifuged, and the supernatant was
analyzed for MMP-2 and MMP-9 levels by gelatin zymog-
raphy as described in the next section.
Migration assays were performed in parallel with inva-
sion assays using cells from the same patients. Migration
assays differed from invasion assays in that uncoated mem-
branes were used (ie, noMatrigel) and they were performed
after a shorter 6-hour incubation period. The chemoattrac-
tant used in migration assays was 10 ng/mL PDGF-BB.
Gelatin zymography. Secretion of MMP-2 and
MMP-9 s was analyzed by gelatin zymography, essentially
as we have described previously,22 except we used 7.4%
polyacrylamide gels. Protocols were optimized for analysis
of either MMP-2 or MMP-9 by regulating exposure time
to incubation buffer (6 hours or 24 hours, respectively).
Conditioned medium from HT-1080 cells (a fibrosarcoma
cell line that constitutively expresses MMP-2 and MMP-9)
was loaded on each gel as a positive control. Gelatinases
were visualized as clear bands of lysis against a dark blue
background of intact substrate. Densitometry was per-
formed on negative scanned images of gels using Image-
Quant software (Amersham Life Science). Of importance
was that paired samples of SV-SMCs and IMA-SMC con-
ditioned media were resolved on the same gel to allow
accurate relative quantification.
Statistical analysis. Results are expressed as mean 
standard error, with n representing the number of different
patients. Differences between treatment groups were ana-lyzed using paired t tests for absolute data or paired ratio t
tests for normalized data (GraphPad Prism software, www.
graphpad.com). P  .05 was considered statistically signif-
icant.
RESULTS
Smooth muscle cell proliferation. The proliferative
properties of paired human SV-SMCs and IMA-SMCswere
first studied in media supplemented with 10% FCS. After
initial cell seeding of equal densities, followed by 72-hour
serum-starvation (day 0), IMA and SV cell numbers re-
mained equivalent (Fig 1, A). After 7 days, however, SV-
SMC exhibited a 6.2-fold mean increase in cell number,
compared with a 3.4-fold increase of IMA-SMCs. Of inter-
est was that the proliferation rates of SV-SMCs and IMA-
SMCs were similar from days 0 to 2, before diverging over
days 4 to 7 (Fig 1, A). Analysis of areas under the prolifer-
ation curves (AUC) revealed that SV-SMCs proliferated at
approximately twice the rate of IMA-SMCs (Fig 1, B).
To determine whether the differences in proliferation
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Fig 1. Comparison of proliferation rates induced by fetal calf
serum (FCS) and p44/42-mitogen-activated protein kinase
(MAPK) activation in smooth muscle cells (SMCs) from the
saphenous vein (SV) and internal mammary artery (IMA). A,
Paired SV-SMCs and IMA-SMC were serum-starved before expo-
sure tomedium containing 10% FCS for 7 days. Cells were counted
every 2 to 3 days to generate a proliferation profile (n  6). Filled
squares, SV-SMC; open circles, IMA-SMC. B, Mean areas under
the proliferation curves (AUC) (arbitrary units) for SV and IMA
cells from each patient. *P  .05, n  6 (paired t-test). C, Whole
cell homogenates from serum-starved cells were prepared and
immunoblotted for phosphorylation (p-MAPK) and expression
(MAPK) of p44/42-MAPK. A representative immunoblot is
shown. D, Pooled densitometry data of relative phospho-MAPK
levels in paired SV-SMCs and IMA-SMC from 10 patients. *P 
.05 (paired ratio t test). Data are presented as means  standard
error of the mean.rates of SV-SMCs and IMA-SMCs might be due to differ-
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measure p44/42-MAPK activation and expression in cells
at the beginning of the proliferation assay. Despite similar
expression levels of MAPK, the amount of phosphorylated
(active) MAPK in SV-SMCs was approximately double that
in IMA-SMCs (Fig 1, C and D).
Because alterations in MAPK signalling are likely to
affect proliferation in response to multiple growth stimuli,
we investigated the proliferative response of SMCs to
PDGF and bFGF, two individual growth factors present in
FCS. SMCs were treated with PDGF-BB (10 ng/mL) or
bFGF (10 ng/mL) inmedia supplemented with 0.4% or 1%
FCS, concentrations that minimized the effects of FCS
whilst maintaining cell survival. Proliferation profiles in
response to individual growth factors (Fig 2) were similar to
those observed with FCS (Fig 1, A). AUC analysis of the
response to PDGF and bFGF revealed that SV-SMCs pro-
liferated at approximately twice the rate of IMA-SMCs,
irrespective of the growth factor or background concentra-
tion of FCS (Table). It is also worth noting that the
proliferative response to PDGF was generally higher than
to bFGF in both cell types (Fig 2 and the Table).
Smooth muscle cell invasion, migration, and matrix
metalloproteinase secretion. We investigated whether
there were intrinsic functional differences between SV-
SMCs and IMA-SMCs at the level of invasion, migration,
and MMP-2/MMP-9 secretion by performing invasion
and migration assays in parallel. Invasion of paired SV-
SMCs and IMA-SMCs was determined using a modified
Boyden chamber assay in which the 8-m pores of the
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Fig 2. Comparison of growth factor-induced proliferation rates
of smooth muscle cells (SMCs) from saphenous vein (SV) and
internal mammary artery (IMA) Paired SV-SMCs (filled squares)
and IMA-SMC (open circles) were serum-starved before exposure
to medium containing either (A) 0.4% fetal calf serum (FCS) plus
platelet-derived growth factor (PDGF); (B) 1% FCS plus PDGF;
(C) 0.4% FCS plus basic fibroblast growth factor (bFGF); or (D)
1% FCS plus bFGF. Cells were counted every 2 to 3 days to
generate a proliferation profile (n  6). Data are presented as
means  standard error of the mean.polycarbonate filter were occluded with Matrigel, an artifi-cial basement membrane matrix. Representative images of
paired SV-SMCs and IMA-SMCs that had invaded to the
underside of the membrane in response to a PDGF/IL-1
stimulus are shown in Fig 3, A.
Quantification of invasion of paired SMCs from five
patients revealed that the invasion rate of SV-SMCs was
approximately 2.1-fold higher than that of IMA-SMCs (Fig
3, B). SMC migration was assessed in parallel by a similar
method to the invasion assay, except in the absence of
Matrigel. The rate of PDGF-induced migration of SV-
SMCs was identical to that of IMA-SMCs (Fig 3, C).
For SMCs to invade towards a chemotactic stimulus,
they must first degrade the Matrigel barrier, a process that
we have previously shown to require both MMP-2 and
MMP-9.25 We therefore used gelatin zymography to ana-
lyze supernatants from the upper chambers of the invasion
assays to determine levels of MMP-2 and MMP-9 secre-
tion. MMP-2 secretion was similar in paired SV-SMCs and
IMA-SMCs (Fig 4, A and B). Similarly, analysis of MMP-9
levels in invasion assay supernatants revealed no difference
between SV-SMCs and IMA-SMCs (Fig 4, C and D).
DISCUSSION
We established in this study that human SV-SMCs
exhibit consistently higher rates of proliferation and inva-
sion and increased MAPK activation compared with paired
IMA-SMCs from the same patient. These intrinsic proper-
ties of SMCs from different vascular beds likely contribute
to the increased susceptibility to intimal hyperplasia of SV
grafts in vivo.
A major strength of our study was the use of human
SMCs from SV and IMA, the exact tissues used as bypass
grafts in CABG patients. Moreover, by performing experi-
ments on paired populations of equal passage cells, we
controlled for interpatient variation in our results. An un-
avoidable limitation of the study was its in vitro nature and
the assumption that the behavior of SMCs in vitro is
comparable with that in vivo. Experiments were performed
under static culture conditions and therefore do not take
Table. Comparison of growth factor-induced
proliferation rates of smooth muscle cells from saphenous
vein and internal mammary artery
Stimulus SV-SMC IMA-SMC P
PDGF (0.4% FCS) 206.3  31.4 94.7  20.6 .0059
PDGF (1% FCS) 333.8  19.0 180.9  33.9 .0087
bFGF (0.4% FCS) 161.1  18.3 80.4  19.7 .0152
bFGF (1% FCS) 231.4  30.2 89.8  27.3 .0066
SV, Saphenous vein; SMC, smooth muscle cell; IMA, internal mammary
artery; PDGF, platelet-derived growth factor; FCS, fetal calf serum; bFGF,
basic fibroblast growth factor.
Analysis of the mean areas under the proliferation curves (arbitrary units) for
PDGF-induced or bFGF-induced proliferation of SV-SMCs and IMA-SMC
in the presence of 0.4% or 1% FCS. Graphs used for analysis are depicted in
Fig 2.
P values, n  6, paired t test.into account certain variables encountered in the in vivo
presented as means  standard error of the mean.
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the architecture of the vein and artery walls. However, our
use of such controlled conditions has highlighted inherent
differences in the behavior of SV-SMCs and IMA-SMCs
that exist independently of hemodynamic factors.
Analysis of the increase in cell number of human SMCs
during a 7-day period revealed that human SV-SMCs con-
sistently proliferated at twice the rate of IMA-SMCs, irre-
spective of the stimulus used (FCS, PDGF, or bFGF). The
differences in cell number were not due to different plating
efficiencies, as the “day 0” counts for the two cell types
(measured 4 days after initial plating) were equivalent.
Although we did not measure PDGF receptor expression in
these cells, others have reported that PDGF receptor ex-
pression is similar in SV-SMCs and IMA-SMCs.21 Thus,
the difference in proliferation rates between the two cell
types is most likely the result of altered activation of key
distal mitogenic-signalling pathways.
Given that the p44/42-MAPK pathway is essential for
proliferation of cultured human vascular SMCs,26 our ob-
servation that SV-SMCs exhibit increased levels of phos-
phorylated (active)MAPK compared with IMA-SMCs pro-
vides a plausible explanation for these differences. The
mechanism underlying the relative increase inMAPK phos-
phorylation in SV-SMCs has yet to be elucidated but likely
reflects either increased activation of the upstream MAPK
kinaseMEK-1/2 or decreasedMAPK phosphatase activity.
In our study it was not attributable to increased MAPK
expression, which was similar in the two cell types.
A number of previous studies have provided supporting
evidence that venous SMCs proliferate at a faster rate than
arterial SMCs,18,21,27,28 although these studies were some-
what limited by the experimental model and design. Yang
et al21 reported that the rate of cell proliferation induced by
FCS and PDGF, as measured by DNA synthesis and cell
number, was higher in human SV-SMCs than in IMA-
SMCs, possibly due to reduced expression of the cell cycle
inhibitor p27Kip1 in SV-SMCs. No difference in short-term
(up to 1 hour) p44/42-MAPK activation was observed
between cell types.21 Unfortunately, these experiments
were not performed with paired populations of cells from
the same patient, making the results less categoric.
In two more recent studies, markers of proliferation
(including DNA synthesis and c-fos expression) were shown
to be higher in human SV-SMCs than in paired populations
of IMA-SMCs after PDGF28 or noradrenaline29 treatment,
although the underlying mechanisms were not explored.
Similarly, commercially available human SV-SMCs have
been shown to exhibit higher levels of PDGF-induced
DNA synthesis than unpaired coronary artery SMCs.18
Increased DNA synthesis is commonly used as a marker of
cell proliferation; however, it does not always equate to
increased cell number. Indeed, a study on rabbit SMC
proliferation reported an increased level of DNA synthesis
after 24 hours in venous SMCs compared with arterial
SMCs, but differences in cell number were not observedA.
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Fig 3. Comparison of invasion and migration rates of smooth
muscle cells (SMCs) from saphenous vein (SV) and internal mam-
mary artery (IMA). Paired SV-SMCs and IMA-SMC were serum-
starved before performing invasion or migration assays towards a
platelet-derived growth factor (PDGF)/interleukin-1 (IL-1) or
PDGF stimulus, respectively. A, Representative images of the
underside of invasion membranes at the end of the experiment
(scale bar  40 m). B, Quantification of the invasion rates of
SV-SMCs and IMA-SMC. Open bars, Control (no chemotactic
stimulus); filled bars, PDGF/IL-1 stimulus. **P  .01 for the
effect of PDGF/IL-1. †† P .01 for comparison of SV-SMCs and
IMA-SMC (n  5, paired t test). C, Quantification of the migra-
tion rates of SV-SMCs and IMA-SMC performed in parallel with
the above invasion assays. Open bars, Control (no chemotactic
stimulus); filled bars. PDGF stimulus. ***P  .001, *P  .05 for
the effect of PDGF.NS,Not statistically significant for comparison
of SV-SMCs and IMA-SMC (n  5, paired t test). Data areuntil 5 days after stimulation.27
error
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ported that the relative increase in human SV-SMC growth
rate compared with IMA-SMCs may be the result of a
relative increase in the apoptotic rate of IMA-SMCs.30 In
that study, however, FCS and PDGF failed to induce an
appreciable increase in IMA-SMC numbers during a 6-day
period, suggesting that culture conditions for IMA-SMCs
were not optimal.30 This is in marked contrast to our own
data that demonstrated significant increases (2.7-fold to
4.4-fold) in IMA-SMC numbers after FCS, PDGF, and
bFGF stimulation during a 7-day period.
Our invasion assay data demonstrated that SV-SMCs
were more than twice as invasive as paired IMA-SMCs and
that this was not due to an increased rate of chemotaxis or
increased levels of MMP-2 or MMP-9 secretion. Although
our study is the first, to our knowledge, to compare inva-
sion rates of human SMCs, rabbit venous SMC invasion
through a type I collagen barrier has been previously shown
to be greater than that of rabbit arterial SMCs.27 In that
study, venous SMCs were also found to secrete higher
levels of MMP-2 and MMP-9 than arterial SMCs, which
contrasts with our present findings in paired human cells.
Our migration data contrast with those of Deng et al,18
in which human SV-SMCs were shown to be more migra-
tory than unpaired human coronary artery SMCs. Also,
migration of SMCs out of tissue explants is reportedly
higher for human SV-SMCs than IMA-SMCs,21,30 al-
though this was not noted in our present study using cells
from paired tissue. Indeed, in our hands, initial tissue
fragment size appears to be themajor determinant of rate of
cellular explant for both SV and IMA. In contrast to all
these studies, human SMCs from atherosclerotic infra-
genicular arteries were found to be more migratory than
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Fig 4. Comparison of matrix metalloproteinase-2 (MM
from saphenous vein (SV) and internal mammary artery (
and MMP-9 secretion using gelatin zymography. A, C
invasion assays after control (C) or platelet-derived gro
Conditioned medium from HT-1080 cells was resolved
densitometry data expressed relative to PDGF/IL-1-trea
filled bars, PDGF/IL-1 stimulus. NS, not statistically sig
paired ratio t-test). Data presented as means  standardSV-SMCs from undiseased vessels.31Anstadt et al19 studied paired SV and IMA tissue ob-
tained from patients undergoing CABG. Using Western
blotting and gelatin zymography, they found that MMP-2
expression was twofold higher in SV than IMA, although
MMP-9 levels were similar. We found no difference in
eitherMMP-2 orMMP-9 secretion in cultured SMCs from
paired SV and IMA, suggesting that the differential gelati-
nase activity in SV and IMA tissue previously reported19 is
not inherent to the SMC but rather is a function of the
different hemodynamic environments that the tissues are
exposed to in vivo.
CONCLUSION
Using paired cultures of human SMCs, we have dem-
onstrated that SV-SMCs are more proliferative and invasive
than IMA-SMCs, likely due to a relative increase in p44/
42-MAPK activation. Having identified these key differ-
ences, future work will focus in more detail on the under-
lying mechanisms. The inherent functional differences
between SMCs of different origins may contribute to the
increased prevalence of intimal hyperplasia in SV grafts
compared with IMA grafts.
We are grateful to Jean Kaye and Parvinder Aley for
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sponsoring Selina Ho.
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